BioAtla (NASDAQ:BCAB) Trading Down 1.3% – Here’s Why

Posted by Brenda Bartman on Sep 15th, 2026

BioAtla, Inc. (NASDAQ:BCAB – Get Free Report) shares fell 1.3% on Monday . The company traded as low as $1.31 and last traded at $1.48. 18,692 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 57,597 shares. The stock had previously closed at $1.50.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioAtla in a research note on Monday, August 31st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioAtla has a consensus rating of “Hold” and a consensus price target of $200.00.

Check Out Our Latest Analysis on BCAB

BioAtla Stock Performance

The company has a market capitalization of $2.47 million, a PE ratio of -0.06 and a beta of 0.71. The business has a fifty day moving average price of $2.97 and a 200 day moving average price of $4.60.

BioAtla (NASDAQ:BCAB – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.50) by $8.64. The firm had revenue of $6.50 million for the quarter, compared to analysts’ expectations of $6.50 million.

Institutional Investors Weigh In On BioAtla

An institutional investor recently raised its stake in BioAtla stock. ADAR1 Capital Management LLC grew its holdings in BioAtla, Inc. (NASDAQ:BCAB – Free Report) by 24.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 228,107 shares of the company’s stock after acquiring an additional 45,000 shares during the period. ADAR1 Capital Management LLC owned about 13.74% of BioAtla worth $37,000 as of its most recent SEC filing. Institutional investors own 77.23% of the company’s stock.

About BioAtla

(Get Free Report)

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.